Testicular Cancer
Seminoma and non-seminomatous germ cell tumours
DefinitionClick to collapse
The provided source text is the NCCN Clinical Practice Guidelines in Oncology for Testicular Cancer, Version 2.2026. This document does not contain a definition for Soft Tissue Sarcoma. The source exclusively covers testicular germ cell tumors, including seminoma and nonseminoma subtypes, their diagnosis, staging, and treatment.
EpidemiologyClick to collapse
The source provides epidemiological data for testicular cancer, not Soft Tissue Sarcoma. Testicular cancer accounts for <1% of new cancer cases, with a majority diagnosed between ages 20 and 34. The global incidence has been rising, with an estimated 9,810 new cases and 630 deaths projected in the United States in 2026. The 5-year relative survival rate is approximately 94%.
SubtypesClick to collapse
Molecular PathogenesisClick to collapse
The source does not describe the molecular pathogenesis of Soft Tissue Sarcoma. It provides limited information on the genetic basis of testicular germ cell tumors, noting that the 2016 WHO classification introduced germ cell neoplasia in situ (GCNIS) as a precursor lesion and distinguished between GCNIS-derived (postpubertal) and unrelated (prepubertal) tumors. Specific driver mutations or pathways for testicular germ cell tumors are not detailed in the provided text.
Risk FactorsClick to collapse
Clinical FeaturesClick to collapse
Typical Presentation
Testicular cancer most often presents as a painless or painful testicular nodule, mass, enlargement, or induration (hardening). Many patients present with testicular discomfort or swelling suggestive of epididymitis or orchitis. Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are broadly categorized into two main histologic subtypes: seminoma and nonseminoma. Seminomas and nonseminomas typically occur at about the same rate, but nonseminomas tend to be more aggressive and often include multiple cell types. The four types of nonseminomas are embryonal carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. Most nonseminomas are mixed tumors of these four subtypes. Testicular cancer accounts for <1% of new cancer cases with a majority of patients being diagnosed between the ages of 20 and 34 years. The global incidence has been steadily rising over the past several decades, with an estimated 9,810 new cases projected in the United States in 2026 [MS-2]. Several risk factors have been identified, including personal or family history of testicular cancer and cryptorchidism [MS-2]. An estimated 630 deaths will occur from testicular cancer in the United States in 2026, reflecting the excellent 5-year relative survival rate (~94%) [MS-2].
Symptoms
Painless testicular nodule or mass
Most common presentation; a firm, hard mass within the testis that may be painless or painful.
Testicular discomfort or swelling
Often mistaken for or suggestive of epididymitis or orchitis; patients may have received a trial of antibiotics which is never warranted in a suspicious mass but can be considered in pain without a mass.
Testicular induration (hardening)
Hardening of the testicular tissue detected on physical examination.
Testicular enlargement
Diffuse or focal enlargement of the testis.
Gynecomastia
Breast enlargement may occur due to hormonal effects of hCG-producing tumors.
Low back or flank pain
May indicate retroperitoneal lymphadenopathy from metastatic disease.
Supraclavicular lymphadenopathy
Enlarged lymph nodes of the lower neck or upper chest, indicating lymphatic spread.
Retroperitoneal mass symptoms
Abdominal fullness, nausea, or early satiety from large retroperitoneal nodal masses.
Neurologic symptoms
Headache, seizures, focal deficits, or altered mental status may indicate brain metastases.
Symptoms of disseminated disease
Weight loss, fatigue, dyspnea from pulmonary metastases, bone pain from skeletal metastases.
Signs
Palpable testicular mass
Firm, often painless mass on physical examination; the most characteristic sign.
Testicular induration or enlargement
Hardening or enlargement of the testis on palpation.
Gynecomastia
Bilateral breast enlargement on physical examination.
Supraclavicular lymphadenopathy
Palpable lymphadenopathy in the supraclavicular fossa.
Abdominal or retroperitoneal mass
Palpable abdominal mass on examination.
Red FlagsClick to collapse
Rapidly increasing beta-hCG or AFP levels in the setting of a testicular mass and symptoms of disseminated disease — may warrant initiating chemotherapy immediately without waiting for orchiectomy or biopsy [TEST-1, MS-5]
Testicular mass with markedly elevated post-orchiectomy serum beta-hCG >5,000 IU/L — may indicate presence of nonseminomatous tumor elements and risk of brain metastases; brain MRI recommended [SEM-1, MS-15]
Testicular mass with elevated serum AFP — indicates presence of nonseminomatous elements, even in histologically pure seminoma; further workup required before treatment [TEST-1, MS-3]
Beta-hCG >1,000 IU/L in a patient with histologically pure seminoma — possibility of nonseminoma should be considered; specimen should be re-reviewed with pathology and referral to a high-volume center recommended [MS-7, MS-12]
Non-pulmonary visceral metastases (bone, liver, brain) — indicates at minimum intermediate-risk disease in seminoma [TEST-D, MS-7]
Extensive lung metastases — may indicate poor-risk nonseminoma and need for brain MRI [MS-3, NSEM-1]
Neurologic symptoms — brain MRI recommended [SEM-1, MS-3]
AFP >10,000 ng/mL — indicates poor-risk nonseminoma [TEST-D, MS-23]
Beta-hCG >50,000 IU/L — indicates poor-risk nonseminoma [TEST-D, MS-23]
LDH >10 x upper limit of normal — indicates poor-risk nonseminoma [TEST-D, MS-23]
Mediastinal primary nonseminoma — classified as poor-risk disease; should be treated with VIP or BEP with careful pulmonary function monitoring [MS-17, NSEM-1]
Testicular mass with features concerning for malignancy on ultrasound (heterogeneous, hypoechoic, vascular) — do not delay orchiectomy for additional imaging [MS-3, TEST-1]
Elevated or rising serum tumor markers (AFP, beta-hCG) after orchiectomy — may indicate occult or residual metastatic disease requiring further workup [MS-4, MS-5]
InvestigationsClick to collapse
Diagnostic
History and physical examination
Initial evaluation to identify testicular mass, lymphadenopathy, gynecomastia, and symptoms of disseminated disease.
Testicular ultrasound with Doppler
Confirm presence of a testicular mass, determine if intra- or extratesticular, and evaluate the contralateral testis. Should be performed if testicular cancer is considered. Transscrotal biopsies should NOT be performed as scrotal violation increases risk of local recurrence.
Serum alpha-fetoprotein (AFP)
Mandatory serum tumor marker. AFP is associated with yolk sac tumors but can also be elevated in embryonal carcinoma or teratoma. Seminomas do NOT produce AFP; elevated AFP in histologic pure seminoma indicates nonseminomatous elements. Expected half-life is 5-7 days. Mildly elevated non-rising levels <20 ng/mL may not indicate GCT. Used for staging, prognosis, and monitoring treatment response.
Serum beta-human chorionic gonadotropin (beta-hCG)
Mandatory serum tumor marker. Most commonly elevated marker in testicular cancer. Can be elevated in both seminomatous and nonseminomatous tumors. Expected half-life is ≤3 days. Used for staging, prognosis, and monitoring treatment response. Further workup needed before treatment for mildly elevated beta-hCG (generally <20 IU/L) as hypogonadism, hyperthyroidism, cannabis use, and heterophile antibodies can cause false-positive results.
Serum lactate dehydrogenase (LDH)
Mandatory serum tumor marker for risk stratification when starting first-line chemotherapy. Less specific than AFP and beta-hCG. Not generally used to monitor for relapse due to false-positive elevations. Important for IGCCCG risk classification. Should not be used alone to make treatment decisions when mildly elevated (<2.5 x ULN).
Chemistry profile
Baseline assessment including renal function (GFR) which is relevant for bleomycin and cisplatin dosing, and liver function. Consider measuring baseline levels of gonadal function.
Radical inguinal orchiectomy
Gold standard for diagnosis and initial management of suspected testicular cancer. Provides histopathologic diagnosis and pathologic staging (pT). Trans-scrotal orchiectomy is discouraged due to higher rates of local recurrence. May consider testis-sparing surgery (partial orchiectomy) in select patients (bilateral tumors, solitary testicle with adequate function).
Testis-sparing surgery (TSS) / partial orchiectomy
Can be considered in select patients: equivocal mass in bilateral otherwise normal testes, synchronous bilateral tumors, solitary testicle with adequate gonadal function. Frozen section of tumor and surrounding parenchyma by experienced genitourinary pathologist should be performed. Higher risk of local recurrence; continued surveillance needed.
Staging
Abdomen/pelvis CT scan with contrast
Essential for assessing retroperitoneal lymph nodes, which are the primary site of metastatic spread. Should be performed unless done prior to orchiectomy. Recommended within 4 weeks prior to initiation of chemotherapy, RPLND, or RT to confirm staging, even if scan was performed previously. For stage I seminoma, pelvis should be included in imaging for patients with discontinuous spermatic cord invasion (pT3) due to higher risk of pelvic relapse.
Abdomen/pelvis MRI with and without contrast
Alternative to CT for staging assessment. Can be considered for surveillance instead of CT (TRISST trial demonstrated noninferiority of MRI to CT for stage I seminoma surveillance). MRI protocol should include visualization of retroperitoneal and pelvic nodes. Use same imaging modality throughout surveillance.
Chest x-ray
Part of standard staging workup. May be used for routine follow-up. In stage I seminoma and nonseminoma, routine chest x-ray may have limited value for detecting relapse — studies show relapses detected by rising markers and/or CT rather than chest x-ray alone. Chest CT with contrast is preferred in presence of thoracic symptoms.
Chest CT with contrast
Recommended if abdomen/pelvis CT/MRI or chest x-ray shows evidence of metastatic disease. Should be performed at baseline if supradiaphragmatic disease present. Preferred over chest x-ray in presence of thoracic symptoms.
Brain MRI with and without contrast
Indicated if clinically indicated based on: beta-hCG >5,000 IU/L, non-pulmonary visceral metastases, extensive lung metastases, neurologic symptoms, AFP >10,000 ng/mL, predominance of choriocarcinoma. Patients with post-orchiectomy serum beta-hCG >5,000 IU/L are at increased risk of brain metastases.
FDG-PET/CT (skull base to mid-thigh)
NOT indicated for initial staging of testicular GCTs. Should NOT be used for staging nonseminoma. In seminoma, may be considered for evaluating residual masses >3 cm after primary chemotherapy (at least 6 weeks post-chemotherapy). Negative FDG-PET/CT is very reassuring. Positive results should lead to resection or biopsy consideration. Not indicated for residual masses ≤3 cm. Has no role in assessing treatment response in nonseminoma post-chemotherapy.
Scrotal ultrasound (repeat)
Should be repeated to rule out contralateral testis mass if not conducted in the last 3 months, particularly for stage IS workup and in patients with bilateral testicular abnormalities, cryptorchidism, or marked atrophy.
Biomarkers
Serum alpha-fetoprotein (AFP)
Essential for staging, prognosis, and treatment monitoring. Seminomas do NOT produce AFP; elevated AFP indicates nonseminomatous elements. Expected half-life is 5-7 days. Decisions to treat should not be based solely on AFP values <20 ng/mL. AFP is most associated with yolk sac tumors but can also be elevated in embryonal carcinoma or teratoma.
Serum beta-human chorionic gonadotropin (beta-hCG)
Essential for staging, prognosis, and treatment monitoring. Most commonly elevated marker. Quantitative analysis of beta subunit. Expected half-life is ≤3 days. Mildly elevated beta-hCG (generally <20 IU/L) requires further workup as hypogonadism, hyperthyroidism, cannabis use, and heterophile antibodies can cause false positives.
Serum lactate dehydrogenase (LDH)
Used for IGCCCG risk classification at initiation of first-line chemotherapy. Not generally used to monitor for relapse due to false-positive elevations. LDH is a less specific marker compared to AFP and beta-hCG. For good-risk seminoma, LDH >2.5 x ULN is associated with worse prognosis.
Molecular testing (NGS and IHC)
Recommended for third-line therapy to assess eligibility for pan-cancer, tumor-agnostic, biomarker-directed therapies for patients with actionable mutations. Should include both next-generation sequencing (NGS) and immunohistochemistry (IHC) testing.
StagingClick to collapse
AJCC 8th Edition TNM Staging Classification (2017) with serum marker (S) component unique to testicular cancer
T Categories
| Stage | Description |
|---|---|
| cTX | Primary tumor cannot be assessed |
| cT0 | No evidence of primary tumor |
| cTis | Germ cell neoplasia in situ |
| cT4 | Tumor invades scrotum with or without vascular/lymphatic invasion |
| pTX | Primary tumor cannot be assessed |
| pT0 | No evidence of primary tumor |
| pTis | Germ cell neoplasia in situ |
| pT1 | Tumor limited to testis (including rete testis invasion) without lymphovascular invasion. Substage pT1a: tumor smaller than 3 cm. Substage pT1b: tumor 3 cm or larger. |
| pT2 | Tumor limited to testis (including rete testis invasion) with lymphovascular invasion OR tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion |
| pT3 | Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion. NOTE: The Panel recommends staging tumors with discontinuous invasion of the spermatic cord as pT3 (high-risk stage I) and NOT as M1 (stage III) as recommended by the 8th edition AJCC [ST-1, MS-5, MS-17]. |
| pT4 | Tumor invades scrotum with or without lymphovascular invasion |
N Categories
| Stage | Description |
|---|---|
| cNX | Regional lymph nodes cannot be assessed |
| cN0 | No regional lymph node metastasis |
| cN1 | Metastasis with a lymph node mass 2 cm or smaller in greatest dimension OR multiple lymph nodes, none larger than 2 cm in greatest dimension |
| cN2 | Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension OR multiple lymph nodes, any one mass larger than 2 cm but not larger than 5 cm in greatest dimension |
| cN3 | Metastasis with a lymph node mass larger than 5 cm in greatest dimension |
| pNX | Regional lymph nodes cannot be assessed |
| pN0 | No regional lymph node metastasis |
| pN1 | Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension |
| pN2 | Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor |
| pN3 | Metastasis with a lymph node mass larger than 5 cm in greatest dimension |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastases |
| M1 | Distant metastases |
| M1a | Non-retroperitoneal nodal or pulmonary metastases |
| M1b | Non-pulmonary visceral metastases |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage 0 | pTis N0 M0 S0 | Germ cell neoplasia in situ (GCNIS) — precursor lesion | None | curative |
| Stage I | pT1-T4 N0 M0 SX | Disease limited to the testis with normal post-orchiectomy markers. Overall survival for stage I approaches 100% regardless of management strategy. | ~100% overall survival for stage I | curative |
| Stage IA | pT1 N0 M0 S0 | Tumor limited to testis without lymphovascular invasion; normal post-orchiectomy markers | ~100% | curative |
| Stage IB | pT2, pT3, or pT4 N0 M0 S0 | Tumor with lymphovascular invasion, spermatic cord invasion, or scrotal invasion; normal post-orchiectomy markers | ~100% | curative |
| Stage IS | Any pT/TX N0 M0 S1-3 | Normal imaging but persistently elevated post-orchiectomy serum tumor markers indicating occult metastatic disease. Elevated tumor markers increase risk of disease outside retroperitoneum. | None | curative |
| Stage II | Any pT/TX N1-3 M0 SX | Metastatic disease to retroperitoneal lymph nodes without distant metastases | None | curative |
| Stage IIA | Any pT/TX N1 M0 S0 or S1 | Metastasis with lymph node mass 2 cm or smaller; low-volume nodal disease | None | curative |
| Stage IIB | Any pT/TX N2 M0 S0 or S1 | Metastasis with lymph node mass 2-5 cm; moderate-volume nodal disease | None | curative |
| Stage IIC | Any pT/TX N3 M0 S0 or S1 | Metastasis with lymph node mass >5 cm; bulky nodal disease | None | curative |
| Stage III | Any pT/TX Any N M1 SX | Distant metastatic disease | None | curative |
| Stage IIIA | Any pT/TX Any N M1a S0 or S1 | Non-retroperitoneal nodal or pulmonary metastases with low-to-normal tumor markers | None | curative |
| Stage IIIB | Any pT/TX N1-3 M0 S2 OR Any pT/TX Any N M1a S2 | Moderate tumor marker elevation (LDH 1.5-10 x N, hCG 5,000-50,000, or AFP 1,000-10,000) with nodal or pulmonary metastases | None | curative |
| Stage IIIC | Any pT/TX N1-3 M0 S3 OR Any pT/TX Any N M1a S3 OR Any pT/TX Any N M1b Any S | High tumor marker elevation (LDH >10 x N, hCG >50,000, or AFP >10,000) or non-pulmonary visceral metastases | None | curative |
Staging Pearls
- The AJCC TNM staging system incorporates serum tumor marker elevation as a distinct category (S), which is unique to this organ site [MS-5]
- Stage I staging is pathologic (p) staging assigned after orchiectomy; clinical staging uses 'c' prefix [MS-5]
- The 8th edition AJCC introduced invasion of epididymis and hilar soft tissue as pathologic criteria for T classification of stage I GCTs, but the Panel discourages using these for clinical decision-making as they have not been validated for relapse prediction — instead, the Panel recommends using lymphovascular invasion, spermatic cord invasion, and scrotal invasion as risk factors [MS-5]
- The Panel recommends staging tumors with discontinuous spermatic cord invasion as pT3 (high-risk stage I) rather than pM1 (stage III) as recommended by the 8th edition AJCC, due to concern about overtreatment and lack of outcome difference data [ST-1, MS-5, MS-17]
- If surveillance is elected for patients with discontinuous spermatic cord invasion, pelvis should be included in imaging due to higher risk of pelvic relapses [SEM-1, NSEM-1]
- Mediastinal primary seminoma should be treated by risk status used for gonadal seminomas with etoposide/cisplatin for 4 cycles or bleomycin/etoposide/cisplatin for 3 cycles [SEM-1]
- Mediastinal primary nonseminoma is poor-risk disease and should be treated with either VIP or BEP with careful pulmonary functioning monitoring [NSEM-1, MS-17]
- Stage IIIB does not apply to pure seminomas — patients with elevated AFP have nonseminomas; in patients with serum beta-hCG >1,000 IU/L, consider possibility of nonseminoma, re-review surgical specimen with pathology, and consider discussion with a high-volume center [SEM-4, MS-7]
- Beta-hCG alone should not be used to stage or risk stratify patients with pure seminoma; use of LDH to risk stratify metastatic seminoma is controversial [SEM-4, MS-7]
- For select cases of clinical stage IIA disease with borderline retroperitoneal lymph nodes, waiting 4-8 weeks and repeating imaging (CT or MRI) to confirm staging before initiating treatment can be considered [SEM-3, NSEM-3]
- Germ cell tumors are not graded [ST-3]
- In 2016, the WHO tumor classification was modified: germ cell neoplasia in situ (GCNIS) is the recommended term for precursor lesions; spermatocytic seminoma was renamed spermatocytic tumor; reporting of anaplasia or distinguishing mature from immature teratoma is not required [MS-6]
- Histologic grade (G) is not used for germ cell tumors [ST-3]
- The 5-year overall survival for all testicular cancer is approximately 94% [MS-2]
- The IGCCCG Update Model (2021) identified LDH >2.5 x ULN, increasing age, and presence of lung metastases as additional adverse prognostic factors [MS-7]
Management PrinciplesClick to collapse
Testicular germ cell tumors (GCTs) are highly curable malignancies requiring a multidisciplinary approach integrating surgery, systemic therapy, and radiation therapy based on histologic subtype (seminoma vs nonseminoma), stage, and risk classification. The NCCN Guidelines provide evidence-based recommendations for all stages of testicular GCTs with the goal of maximizing cure rates while minimizing unnecessary side effects, complications, and late toxicities. Testicular GCTs are broadly categorized into seminoma and nonseminoma subtypes, which have different natural histories and treatment approaches. When both seminoma and nonseminoma elements are present, management follows nonseminoma guidelines. Together, these guidelines aim to maximize the potential for cure and to avoid unnecessary side effects, complications, and late toxicities [MS-2].
Curative
All stages of testicular GCTs
The primary goal is cure with treatment intensity adapted to disease stage and risk. Stage I disease has cure rates approaching 100% regardless of management strategy. Even metastatic disease is cured in the majority of patients, with 5-year overall survival rates of 96% for good-risk disease, 89% for intermediate-risk, and 67% for poor-risk nonseminoma per IGCCCG update data [MS-23].
Risk-adapted treatment
Stage I nonseminoma
Risk factors for recurrence include lymphovascular invasion (LVI), invasion of spermatic cord, or invasion of scrotum. Some centers consider predominance of embryonal carcinoma as an additional risk factor. Surveillance is preferred for low-risk patients while all three options (surveillance, RPLND, or adjuvant BEP x1) should be carefully considered for high-risk patients [MS-18].
Risk-adapted treatment
Metastatic disease
IGCCCG risk classification guides first-line chemotherapy intensity: good-risk disease (3 cycles BEP or 4 cycles EP), intermediate-risk (4 cycles BEP preferred), and poor-risk (4 cycles BEP preferred or 4 cycles VIP for patients at risk for bleomycin toxicity) [TEST-D, TEST-E].
Multidisciplinary team involvement is essential. The guidelines recommend referral to high-volume centers for: patients with poor-risk disease [MS-23], residual masses with abnormal AFP and/or beta-hCG levels [NSEM-7], retroperitoneal lymph node dissection (RPLND) [TEST-H], post-chemotherapy RPLND in complex cases [TEST-H], brain metastases treatment planning [MS-28], and extragonadal germ cell tumors [TEST-D]. Shared decision-making with patients is recommended for stage IIA/IIB seminoma treatment options [SEM-3]. Social work referral is recommended considering social determinants of health that may affect treatment follow-through [SEM-1].
Performance status assessment guides treatment intensity. Poor-risk patients with mediastinal primary nonseminoma require VIP or BEP with careful pulmonary functioning monitoring [MS-17]. Bleomycin-free regimens should be considered in patients at increased risk for bleomycin toxicity including those with reduced GFR, older age, or lung disease [TEST-E]. G-CSFs should be used with high-risk febrile neutropenia regimens including TIP, VeIP, and VIP [TEST-F]. The guidelines do not provide specific performance status cutoffs but emphasize individualized treatment decisions.
Management PathwaysClick to collapse
Branching: Pathologic stage (IA vs IB), Patient preference and ability to comply with surveillance, Risk factors including tumor size and rete testis invasion, Contraindications to specific treatments
Branching: Persistent elevation of serum tumor markers post-orchiectomy, Radiographic evidence of metastatic disease, Marker trajectory
Branching: Lymph node mass size (<3 cm vs 3-5 cm), Bulky vs non-bulky disease, Patient preference and shared decision-making, Borderline lymph nodes
Branching: IGCCCG risk classification, Presence of non-pulmonary visceral metastases, LDH levels >2.5x ULN in good-risk patients
Branching: Residual mass size (>3 cm vs ≤3 cm), Serum AFP and beta-hCG levels, FDG-PET/CT results
Branching: Presence of risk factors (LVI, spermatic cord invasion, scrotal invasion), Patient preference, Ability to comply with surveillance
Branching: Serum tumor marker levels, Lymph node size and distribution, Disease confined to landing zones vs aberrant drainage, Presence of somatic type malignancy
Branching: IGCCCG risk classification, Primary tumor site, Serum marker levels, Brain metastases presence
Branching: Residual mass size, Serum AFP and beta-hCG levels, Pathology of resected tissue, Marker kinetics
Branching: Prior treatment history, Timing of relapse, Response to prior therapy
Branching: Prior treatment history, Timing of relapse (≤2 years vs >2 years), Resectability, Marker levels
Pretreatment EvaluationClick to collapse
Initial evaluation
Staging imaging
Pathologic diagnosis
Fertility and psychosocial
SurgeryClick to collapse
Radical inguinal orchiectomy is the gold standard for diagnosis and initial management of suspected testicular cancer. Retroperitoneal lymph node dissection (RPLND) serves both diagnostic and therapeutic roles for staging and treatment of retroperitoneal disease.
Radical inguinal orchiectomy is the gold standard; trans-scrotal orchiectomy is discouraged due to scrotal violation associated with higher local recurrence rates and altered metastatic dissemination pathways [TEST-H].
When patient presents with rapidly increasing beta-hCG or AFP, metastatic disease on imaging, and symptoms of disseminated disease, chemotherapy can be initiated immediately without waiting for orchiectomy. However, radical inguinal orchiectomy should be performed at completion of chemotherapy [TEST-H].
Testis-sparing surgery (TSS) can be considered in select patients through inguinal approach with frozen section analysis [TEST-H].
Sperm banking should be discussed with reproductive age patients prior to any therapeutic intervention that may compromise fertility [TEST-H].
For equivocal mass <2 cm with normal AFP and beta-hCG, short-interval imaging can be considered prior to partial orchiectomy [TEST-H].
Use of testicular prosthesis should be discussed prior to radical inguinal orchiectomy [TEST-H].
Procedures
Radical inguinal orchiectomy
Primary treatment for most patients with suspicious testicular mass on ultrasound [TEST-H, MS-5].
Nerve-sparing retroperitoneal lymph node dissection (RPLND)
Primary RPLND for stage I nonseminoma and select stage II; post-chemotherapy RPLND for residual retroperitoneal masses in nonseminoma [TEST-H, MS-18].
Testis-sparing surgery (partial orchiectomy)
Select patients: equivocal mass <2 cm with normal markers, synchronous bilateral tumors, solitary testicle with adequate gonadal function [TEST-H].
Post-chemotherapy RPLND
Residual retroperitoneal mass (>1 cm on axial imaging) following systemic chemotherapy with normalized serum tumor markers in nonseminoma [TEST-H, MS-22].
Surgical resection of residual masses
Residual masses after second-line chemotherapy with normal markers [NSEM-9].
Radiation TherapyClick to collapse
RT is used in the management of pure seminoma for adjuvant treatment of stage I disease and primary treatment of stage IIA/IIB non-bulky disease. It is not used for nonseminoma management.
Principles
- Modern radiotherapy involves smaller fields and lower doses than historically used [TEST-C].
- CT-based AP-PA 3D-CRT has lower Dmean and D50% for kidneys, liver, and bowel compared to IMRT. IMRT is not necessary. Proton therapy can be considered [TEST-C].
- RT should start once orchiectomy wound has fully healed. Patients treated 5 days per week [TEST-C].
- Antiemetic prophylaxis encouraged at least 2 hours prior to each treatment [TEST-C].
- Discussion of semen analysis and sperm banking prior to treatment if clinically indicated [TEST-C].
- Non-contrast CT simulation with patient supine, arms at sides, in treatment position [TEST-C].
- All patients except those with bilateral orchiectomy should be treated with scrotal shield [TEST-C].
- Linear accelerators with >6 MV photons should be used when possible [TEST-C].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indications |
|---|---|---|---|---|---|
| Stage I Seminoma Adjuvant RT | 20 Gy (preferred), 25.5 Gy, 19.8 Gy, or 21.6 Gy | 2.0 Gy, 1.5 Gy, 1.8 Gy, or 1.8 Gy respectively | 10, 17, 11, or 12 respectively | Daily fractions over 2-3.5 weeks | Adjuvant treatment for stage I seminoma after orchiectomy [TEST-C]. |
| Stage IIA Seminoma RT | 30 Gy (1-2 cm disease) | 1.8-2.0 Gy | Approximately 16-17 fractions | Two consecutive phases: modified dog-leg fields to 20-25.5 Gy then cone down | Clinical stage IIA seminoma with non-bulky disease [TEST-C]. |
| Stage IIB Seminoma RT | 36 Gy (2-3 cm disease) | 1.8-2.0 Gy | Approximately 20 fractions | Two consecutive phases: modified dog-leg fields to 20-25.5 Gy then cone down | Clinical stage IIB seminoma with non-bulky disease [TEST-C]. |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Para-aortic Strip Fields RT (Stage I) | 20 Gy in 10 fractions of 2.0 Gy each (preferred) or alternative schedules | None | Stage I seminoma adjuvant treatment | MRC TE18/EORTC 30942 trial comparing 20 Gy vs 30 Gy showing no difference in relapse rates [MS-10] | Late toxicities including secondary malignancies, potential cardiovascular effects. Long-term follow-up studies indicate increased late toxicities with RT [MS-10]. |
| Modified Dog-Leg Fields + Cone Down (Stage IIA/B) | Initial phase: 20-25.5 Gy; Cone down to 30 Gy (IIA) or 36 Gy (IIB) | None (separate approach from chemotherapy) | Clinical stage IIA/IIB seminoma | Classen et al trial establishing standard field arrangements [MS-14] | Acute: nausea, fatigue, diarrhea. Late: secondary malignancies, potential cardiovascular effects [MS-14] |
| Carboplatin + Involved-Node RT (SAKK 01/10) | Single-dose carboplatin followed by involved-node RT | Sequential, not concurrent | Stage IIA/IIB seminoma (category 2B) | SAKK 01/10: 3-year PFS 93.7% [SEM-3, MS-14] | Grade 3-4: neutropenia 4%, thrombocytopenia 3%, vomiting 1%. No treatment-related deaths or late toxic effects reported [MS-14] |
Systemic TherapyClick to collapse
Systemic therapy is the primary treatment for metastatic germ cell tumors and is based on cisplatin combination chemotherapy. The IGCCCG risk classification system guides treatment intensity. For stage I nonseminoma, adjuvant chemotherapy with one cycle of BEP reduces relapse risk. Testicular GCTs are highly chemosensitive with cure rates of approximately 90% for good-risk disease [MS-23].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Treatment Response Assessment for Testicular GCTs
Timing
Post-chemotherapy response assessment with CT scan with contrast or MRI with and without contrast of chest, abdomen, pelvis should be performed within 1 month of completing chemotherapy. FDG-PET/CT should be performed at least 6 weeks following completion of chemotherapy when indicated. For surveillance, imaging schedules vary by stage and treatment modality [TEST-I, TEST-A, TEST-B].
SurveillanceClick to collapse
ComplicationsClick to collapse
Supportive CareClick to collapse
PrognosisClick to collapse
Follow UpClick to collapse
Key TrialsClick to collapse
Clinical PearlsClick to collapse
Special SituationsClick to collapse
Guidelines ResourcesClick to collapse
Protective FactorsClick to collapse
The source does not mention any protective factors for Soft Tissue Sarcoma. The provided text focuses solely on the diagnosis and management of testicular germ cell tumors and does not discuss preventive measures or protective factors for any soft tissue malignancy.